Xilio Therapeutics (XLO) Retained Earnings (2020 - 2026)
Xilio Therapeutics (XLO) posted Retained Earnings of $500.9 million for Q1 2026, up 10.31% sequentially from $454.1 million in Q4 2025, and up 226.16% YoY from $153.6 million in Q1 2025.
Xilio Therapeutics (XLO) Retained Earnings (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Retained Earnings for 7 years, with the latest figure at $500.9 million in Q1 2026.
- Quarterly Retained Earnings rose 226.16% year-over-year to $500.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $500.9 million (up 226.16% YoY) and the FY2025 annual result came in at $454.1 million, up 218.32% from the prior year.
- Retained Earnings rose to $500.9 million in Q1 2026 per XLO's latest filing, from $454.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $500.9 million in Q1 2026 and troughed at -$429.1 million in Q3 2025.
- A 5-year average of -$84.1 million and a median of -$307.9 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 349.98% in 2022, then slumped 196.12% in 2024.
- Over 5 years, Retained Earnings stood at $354.8 million in 2022, then slumped by 191.76% to -$325.5 million in 2023, then decreased by 17.89% to -$383.8 million in 2024, then surged by 218.32% to $454.1 million in 2025, then grew by 10.31% to $500.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $500.9 million, $454.1 million, and -$429.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | 506.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 506.95 Mn |
| Mar 31, 2026 | 500.86 Mn |
| Dec 31, 2025 | 454.06 Mn |
| Sep 30, 2025 | -429.10 Mn |
| Jun 30, 2025 | -412.90 Mn |
| Mar 31, 2025 | -397.00 Mn |
| Dec 31, 2024 | -383.75 Mn |
| Sep 30, 2024 | -370.70 Mn |
| Jun 30, 2024 | -356.60 Mn |
| Mar 31, 2024 | -342.72 Mn |
| Dec 31, 2023 | -325.51 Mn |
| Sep 30, 2023 | -307.90 Mn |
| Jun 30, 2023 | -291.11 Mn |
| Mar 31, 2023 | 356.54 Mn |
| Dec 31, 2022 | 354.75 Mn |
| Sep 30, 2022 | 352.94 Mn |
| Jun 30, 2022 | 351.07 Mn |
| Mar 31, 2022 | -182.24 Mn |
| Dec 31, 2021 | 346.31 Mn |
| Sep 30, 2021 | -141.19 Mn |